Embecta (NASDAQ: EMBC) net income
Embecta reported a net profit of $95.4m for fiscal 2025, 21.8% more than in fiscal 2024 ($78.3m). Its net margin was 8.8%. Earnings per share were $1.64.
Embecta has grown its net income for 2 years in a row, and its best year of the last 5 was fiscal 2021. The biggest drop was in fiscal 2023, −68.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $95.4m | +21.8% | 8.8% | $1.64 |
| 2024 | $78.3m | +11.2% | 7.0% | $1.36 |
| 2023 | $70.4m | −68.5% | 6.3% | $1.23 |
| 2022 | $223.6m | −46.1% | 19.8% | $3.92 |
| 2021 | $414.8m | — | 35.6% | $7.28 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Embecta net income compared with its sector
By net income for its latest fiscal year, Embecta ranks 116th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Embecta, 8.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 114th | Haemonetics | $97.3m | 7.3% |
| 115th | Addus HomeCare | $95.9m | 6.7% |
| 116th | Embecta | $95.4m | 8.8% |
| 117th | Keros Therapeutics | $87.0m | 35.7% |
| 118th | Zevra Therapeutics | $83.2m | 78.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Embecta
- How much did Embecta earn in fiscal 2025?
- Embecta reported a net profit of $95.4m for fiscal 2025. In fiscal 2024 it reported a net profit of $78.3m.
- What are the earnings per share of Embecta?
- They were $1.64 in fiscal 2025, compared with $1.36 in fiscal 2024.
- What is the net margin of Embecta?
- In fiscal 2025 its net profit was 8.8% of its revenue.
- What was the most profitable year for Embecta?
- Of its last 5 fiscal years, fiscal 2021, with $414.8m.
- Where does Embecta rank in its sector by net income?
- It ranks 116th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Embecta come from?
- From the annual report (Form 10-K) that Embecta files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Embecta files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Embecta: the Embecta page · annual accounts · revenue · dividends paid · insider transactions.
Dividend per share of Embecta by fiscal year, with the filing behind every figure: Embecta dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.